Jyong Biotech Ltd. (ticker: MENS) is a pioneering biotechnology firm focused on developing advanced therapeutic solutions for cancer and autoimmune diseases. The company leverages its expertise in genomics and molecular biology to cultivate a diverse pipeline of innovative treatments, supported by a compelling intellectual property portfolio. Through strategic collaborations within the biopharmaceutical sector, Jyong Biotech is well-positioned to capitalize on emerging market opportunities while prioritizing scientific rigor and patient-centric approaches, establishing itself as a key player in the evolution of healthcare innovation.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-2.51M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -12.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.34 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $74.23M |
| Float | $26.94M |
| % Insiders | 62.20% |
| % Institutions | 0.71% |
Volatility is currently contracting